SEC Form 4 · accession 0001645470-19-000017
ENDONOVO THERAPEUTICS, INC. · ENDV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan Brian Collier
Officer — CEO
Period of report
Mar 5, 2019
Accepted (ET)
Mar 8, 2019 · 2:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001528172
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 5, 2019 | P | 5,000 | $0.0207 | A | 21,694,623 | D | |
| Common Stock | Mar 5, 2019 | P | 10,000 | $0.021 | A | 21,704,623 | D | |
| Common Stock | Mar 5, 2019 | P | 500 | $0.0207 | A | 21,705,123 | D | |
| Common Stock | Mar 5, 2019 | P | 15,000 | $0.0207 | A | 21,720,123 | D | |
| Common Stock | Mar 5, 2019 | P | 1,000 | $0.0207 | A | 21,721,123 | D | |
| Common Stock | Mar 6, 2019 | P | 5,000 | $0.0186 | A | 21,726,123 | D | |
| Common Stock | Mar 6, 2019 | P | 10,000 | $0.0188 | A | 21,736,123 | D | |
| Common Stock | Mar 6, 2019 | P | 500 | $0.0186 | A | 21,736,623 | D | |
| Common Stock | Mar 6, 2019 | P | 2,000 | $0.0189 | A | 21,738,623 | D | |
| Common Stock | Mar 6, 2019 | P | 5,000 | $0.0188 | A | 21,743,623 | D | |
| Common Stock | Mar 6, 2019 | P | 20,000 | $0.0188 | A | 21,763,623 | D | |
| Common Stock | Mar 6, 2019 | P | 500 | $0.0188 | A | 21,764,123 | D | |
| Common Stock | Mar 6, 2019 | P | 5,000 | $0.0195 | A | 21,769,123 | D | |
| Common Stock | Mar 6, 2019 | P | 2,000 | $0.0207 | A | 21,771,123 | D | |
| Common Stock | Mar 6, 2019 | P | 5,000 | $0.0198 | A | 21,776,123 | D | |
| Common Stock | Mar 6, 2019 | P | 2,000 | $0.0199 | A | 21,778,123 | D | |
| Common Stock | Mar 6, 2019 | P | 5,000 | $0.0198 | A | 21,783,123 | D | |
| Common Stock | Mar 7, 2019 | P | 2,000 | $0.0196 | A | 21,785,123 | D | |
| Common Stock | Mar 7, 2019 | P | 3,000 | $0.0199 | A | 21,788,123 | D | |
| Common Stock | Mar 7, 2019 | P | 5,000 | $0.0203 | A | 21,793,123 | D |
Table II — derivative securities
No Table II lines on this filing.